

Listing of Claims:

1. (Original) An isolated polynucleotide comprising a first polynucleotide sequence or the full complement of the first polynucleotide sequence, wherein the first polynucleotide sequence encodes a polypeptide selected from the group consisting of SEQ ID NO:2 or 4.
2. (Original) The isolated polynucleotide of claim 1, wherein the isolated polynucleotide comprises the first polynucleotide sequence.
3. (Original) The isolated polynucleotide of claim 2, wherein the first polynucleotide sequence encodes the polypeptide consisting of SEQ ID NO:2.
4. (Original) The isolated polynucleotide of claim 3, wherein the isolated polynucleotide consists of the first polynucleotide sequence.
5. (Original) The isolated polynucleotide of claim 2, wherein the first polynucleotide sequence encodes the polypeptide consisting of SEQ ID NO:4.
6. (Original) The isolated polynucleotide of claim 5, wherein the isolated polynucleotide consists of the first polynucleotide sequence.
7. (Original) An expression vector comprising the isolated polynucleotide of claim 1.
8. (Original) A host cell comprising the expression vector of claim 7.
9. (Original) An immunogenic composition comprising the isolated polynucleotide of claim 1 and a pharmaceutically acceptable carrier.
10. (Original) The immunogenic composition of claim 9, further comprising an adjuvant.
11. (Original) An isolated polynucleotide comprising a first polynucleotide or the full complement of the first polynucleotide sequence, wherein the first polynucleotide sequence is selected from the group consisting of SEQ ID NO:1 or 3.
12. (Original) The isolated polynucleotide of claim 11, wherein the isolated polynucleotide comprises the first polynucleotide sequence.

13. (Original) The isolated polynucleotide of claim 12, wherein the first polynucleotide sequence consists of SEQ ID NO:1.
14. (Original) The isolated polynucleotide of claim 13, wherein the isolated polynucleotide consists of the first polynucleotide sequence.
15. (Original) The isolated polynucleotide of claim 12, wherein the first polynucleotide sequence consists of SEQ ID NO:3.
16. (Original) The isolated polynucleotide of claim 15, wherein the isolated polynucleotide consists of the first polynucleotide sequence.
17. (Original) An expression vector comprising the polynucleotide of claim 11.
18. (Original) A host cell comprising the expression vector of claim 17.
19. (Original) An immunogenic composition comprising the isolated polynucleotide of claim 11 and a pharmaceutically acceptable carrier.
20. (Original) The immunogenic composition of claim 19, further comprising an adjuvant.

Remarks/Arguments:

These remarks are responsive to the Office Action dated March 23, 2007.

The indication that claims 1-8 and 11-18 are allowed is noted with appreciation.

The specification has been revised to correct the status of nonprovisional parent applications cited in the first paragraph and to properly designate the term, "TWEEN," as a registered trademark, as requested on page 2 of the Office Action. No new matter has been added by these corrections.

The Office Action asserts on page 2 that the title of the invention is not descriptive and should be changed. However, this is a divisional application of U.S. Appl. No. 09/673,896, now U.S. Pat. No. 6,696,062, which bears the same title. In addition, Applicant points out that the title is descriptive, because BASB006 refers to a defined group of polypeptides from *N. meningitidis*. Therefore, the Applicant respectfully submits that the title is sufficiently descriptive, and that the divisional applications and patents should continue to have the same titles.

On page 3 of the Office Action, claims 9, 10, 19, and 20 are rejected under 35 USC Section 112 as failing to comply with the written description requirement. The Action states that this is a "new matter" rejection. However, claims 9, 10, 19, and 20 are supported by original claims 20 and 25 (from PCT/EP99/02766) and claim 58 from Appl. No. 09/673,896, of which this application is a divisional. Support for these claims may also be found in the specification in paragraphs 0002, 0044, and, in particular, 0075-0076 (describing and enabling genetic immunization), 0103-0109 (describing and enabling production of antibodies to polynucleotides), and 0129-0134 (describing and enabling production of vaccines from polynucleotides and describing immunogenic compositions comprising polynucleotides).

Accordingly, Applicant submits that claims 9, 10, 19, and 20 are adequately described, enabled, and supported by the specification, and, in that respect, these claims are fully compliant with 35 USC Section 112. Therefore, Applicant respectfully requests that the Section 112 rejection of these claims be withdrawn.

Conclusion

For the above reasons, it is respectfully submitted that the claims are in condition for immediate allowance and a notice to this effect is solicited. The Examiner is invited to phone Applicant's attorney if it is believed that a telephonic interview would expedite prosecution of the application.

Respectfully submitted,



Paul F. Prestia, Reg. No. 23,031
Joy Mulholland, Ph.D., Reg. No. 47,810
Attorneys for Applicant

JM/lrb

Dated: September 24, 2007


P.O. Box 980
Valley Forge, PA 19482-0980
(610) 407-0700

The Director is hereby authorized to charge or credit Deposit Account No. **18-0350** for any additional fees, or any underpayment or credit for overpayment in connection herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

September 24, 2007

Date


Lisa Bennett

LB_H:\NRPORTBL\RP\LISA\198976_1.DOC